A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study

Clinical Pharmacology in Drug Development

Volumn 3, Issue 4, 2014, Pages 276-283

  Salinger, David H ^a   Endres, Christopher J ^a   Martin, David A ^a   Gibbs, Megan A ^a  

^a AMGEN INC   (United States)

Author keywords

Brodalumab; Interleukin 17 receptor; Monoclonal antibody; PK PD model; Psoriasis

Indexed keywords

BRODALUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; FEMALE; FIRST IN HUMAN STUDY; HUMAN; HUMAN EXPERIMENT; IC 50; MALE; MICHAELIS MENTEN KINETICS; MULTICENTER STUDY; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SINGLE DRUG DOSE; AUSTRALIA; BIOLOGICAL MODEL; BLOOD; CANADA; CLINICAL TRIAL; NONLINEAR SYSTEM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; AUSTRALIA; CANADA; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903795347     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.103     Document Type: Article

References (32)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol. 2001; 26:314-320.
2. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2:52-72.
3. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012; 366:1190-1199.
4. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366:1181-1189.
5. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129:1339-1350.
6. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013; 133:17-26.
7. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009; 160:319-324.
8. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496-509.
9. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141:185-191.
10. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012; 132:2466-2469.
11. Aarons L, Karlsson MO, Mentre F, et al. Role of modelling and simulation in Phase I drug development. Eur J Pharm Sci. 2001; 13:115-122.
12. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007; 82:21-32.
13. Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA. Clinical trial simulation to inform phase 2: comparison of concentrated vs. distributed first-in-patient study designs in psoriasis. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e58.
14. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res. 2005; 22:1088-1100.
15. Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010; 50:257-267.
16. Hutmacher MM, Nestorov I, Ludden T, Zitnik R, Banfield C. Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. J Clin Pharmacol. 2007; 47:238-248.
17. Hu C, Szapary PO, Yeilding N, Zhou H. Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2011; 38:237-260.
18. Hu C, Yeilding N, Davis HM, Zhou H. Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn. 2011; 38:497-517.
19. Wu B, Joshi A, Ren S, Ng C. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab. J Pharm Sci. 2006; 95:1258-1268.
20. Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol. 2010; 50:494-506.
21. Sharma A, Jusko WJ. Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1996; 24:611-635.
22. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003; 30:387-404.
23. Holford NH. The Visual Predictive Check Superiority to Standard (Rorschach) Plots. Abstracts of the Annual Meeting of the Population Approach Group in Europe; 2005:Abstr. 738 www.page-meeting.org/default.asp?abstract=738
24. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001; 28:231-252.
25. Dong JQ, Salinger DH, Endres CJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011; 50:131-142.
26. Holford NH, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992; 89:11466-11470.
27. Jusko WJ. Conceptualization of drug distribution to a hypothetical pharmacodynamic effect compartment. Clin Pharmacol Ther. 1993; 54:112-113.
28. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol. 2009; 49:1382-1402.
29. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979; 25:358-371.
30. Xu XS, Yuan M, Karlsson MO, Dunne A, Nandy P, Vermeulen A. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J. 2012; 14:927-936.
31. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008; 35:573-591.
32. Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm. 1999; 27:301-323.